Cargando…
Are we ready to withdraw acetylsalicylic acid after complex percutaneous coronary intervention?
Autores principales: | Bufano, Gabriella, Zimarino, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Via Medica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747810/ https://www.ncbi.nlm.nih.gov/pubmed/34985119 http://dx.doi.org/10.5603/CJ.2021.0141 |
Ejemplares similares
-
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial
por: Kubica, Jacek, et al.
Publicado: (2022) -
The effect of acetylsalicylic acid dosed at bedtime on the anti-aggregation effect in patients with coronary heart disease and arterial hypertension: A randomized, controlled trial
por: Krasińska, Beata, et al.
Publicado: (2020) -
Diurnal Variation in Outcomes of Percutaneous Coronary Intervention
por: Malik, Jahanzeb, et al.
Publicado: (2020) -
Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study
por: Liu, Chieh-Yu, et al.
Publicado: (2020) -
Inadvertent Septal Ablation During Percutaneous Coronary Intervention
por: Gao, Feng, et al.
Publicado: (2021)